Vallerie McLaughlin

profile-vallerie-mclaughlin-2023
Kim A Eagle M.D. Endowed Professor of Cardiovascular Medicine
Program Associate, Internal Medicine
Professor of Internal Medicine, Medical School
Office:
Michigan Medicine
Cardiovascular Medicine
1500 E. Medical Center Drive, SPC 5853
Ann Arbor, Michigan 48109-5853
Email:
[email protected]
Phone:
Available to mentor
Vallerie McLaughlin
profile-vallerie-mclaughlin-2023
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • Manage Your Profile

  • Qualifications

    • MD
      Northwestern University Medical School, Evanston, IL, United States
      1985 - 1989
    • BS
      Northwestern University, Evanston, IL, United States
      1981 - 1985

    Center Memberships

    • Center Member
      Samuel and Jean Frankel Cardiovascular Center

    Research Overview

    1. Pulmonary Hypertension
    2. Pulmonary vascular disease

    Recent Publications

    See All Publications
    • Journal Article
      Right Heart Dysfunction in Valvular Heart Disease: Epidemiology, Prognosis, and Management Considerations
      Brener MI, Badano LP, Galloo X, Muraru D, Pinney SP, McLaughlin VV, Hausleiter J, Lurz P, Le Ruz R, van Mieghem NM, Weckbach LT, Ailawadi G, Praz F, Lindman BR, Salavitabar A, Chehab O, Stocker TJ, Lindenfeld J, Leon MB, Burkhoff D, Hahn RT. Journal of the American College of Cardiology, 2026 Nov 10; 88 (19): 2221 - 2243. DOI:10.1016/j.jacc.2026.08.035
    • Journal Article
      Sotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR
      Gomberg-Maitland M, Ghofrani HA, Gibbs JSR, Hoeper MM, Humbert M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Miller B, Lin J, Shi Y, Perchenet L, Strait J, Cornell AG, Badesch DB. Chest, 2026 Nov 1; 170 (5): 1593 - 1598. DOI:10.1016/j.chest.2026.04.056
      PMID: 42208730
    • Journal Article
      Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
      Farber HW, Chakinala MM, Hemnes AR, Chin KM, Highland KB, McLaughlin VV, Melendres-Groves LD, Cho M, Doad G, Fatehi E, Han M, Rahman M, Strachan P, Tobore T, Kim NH. Journal of Racial and Ethnic Health Disparities, 2026 Oct 1; 13 (5): 4283 - 4295. DOI:10.1007/s40615-025-02579-3
      PMID: 40760219
    • Journal Article
      Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
      McLaughlin VV, Solum D, Lachant D, Ataya A, Barberà JA, Meyer GB, Chang SA, Channick R, Church C, Feenstra J, Gaine S, Giannakoulas G, Jerjes-Sanchez C, Khanna D, Kim NH, Oudiz R, Preston IR, Sood N, Torres F, Vachiery JL, Pulido T, Cella D, Deng C, Escudero M, Lacasse V, Peterson L, Benza R, Humbert M. Lancet, 2026 Aug 8; 408 (10554): 521 - 531. DOI:10.1016/S0140-6736(26)01011-1
      PMID: 42520828
    • Journal Article
      Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension
      Osterhout R, Boucly A, Benza RL, Channick RN, Chin KM, Frantz RP, Hemnes AR, Howard LS, McLaughlin VV, Sitbon O, Vachiéry JL, Zamanian RT, Aranda R, Cravets M, Ding Z, Duong-Verlé T, Mottola D, Roscigno RF, Sitapara R, Zisman LS, Bruey JM, Ghofrani HA. American Journal of Respiratory and Critical Care Medicine, 2026 Aug 1; 212 (8): 1832 - 1837. DOI:10.1093/ajrccm/aamag175
      PMID: 42104009
    • Journal Article
      Sotatercept and prostacyclin de-escalation in stable pulmonary arterial hypertension: a single-center case series
      Moles VM, Cascino T, McLaughlin VV. American Journal of Respiratory and Critical Care Medicine, 2026 Aug 1; 212 (8): 1826 - 1828. DOI:10.1093/ajrccm/aamag147
      PMID: 42085278
    • Journal Article
      From Clinical Success to Physiologic Understanding
      Cascino TM, Fudim M, McLaughlin VV. Journal of the American College of Cardiology, 2026 Jul 28; 88 (4): 433 - 436. DOI:10.1016/j.jacc.2026.03.049
      PMID: 42017885
    • Journal Article
      Pulmonary Arterial Hypertension in Octogenarians: The Pulmonary Hypertension Association Registry
      Reddy R, Moutchia J, Ravichandran A, Runo J, Badesch DB, Moss J, Burger C, De Marco T, Horn E, Ataya A, Bryant A, Al-Naamani N, Kawut SM, Willson M, Raina A, Raval A, Muralidhar A, Roberts E, Dong LW, Bakshi S, Ivy DD, Critser P, Hirsch R, Heresi G, Krishnan U, Krishnan S, Sager J, Bensimhon H, Fortin T, Swisher J, Presberg K, Gomberg-Maitland M, Kelly B, Awdish R, Safdar Z, Prohaska C, Shlobin O, Kingrey J, Cirulis M, Mathai S, Moretta D, Wells R, Frantz R, Scott R, Rahul Argula M, Matuschak G, George MP, Boyce P, McConnell JW, Desai S, Kaplan A, Ventetuolo C, Klinger J, Montgomery G, Yung D, Eggert M, Zamanian R, Varghese N, Farr G, Avdalovic M, Saggar R, Channick R, Fineman J, Elwing J, Bull T, Foley R, Cadaret L, Williamson T, Ramani G, McLaughlin V, Thenappan T, Wichman T, Melendres-Groves L, Ford HJ, Chan S, White RJ, Clapham K, Badlam J, Mihalek A, Leary P, Bartolome S, Austin E, Hemnes A, Grinnan D, Chakinala M, Singh I. Pulmonary Circulation, 2026 Jul 1; 16 (3): DOI:10.1002/pul2.70387

    Featured News & Stories

    heart graphic navy and yellow
    Health Lab

    Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis

    Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine by Michigan Medicine.